Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis
Brief Summary: All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3
B: Arm Label: atorvastatin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: Lovaza arm; Type: EXPERIMENTAL; Interventions: Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin | Intervention Type: DRUG; Name: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin; Assigned to Arm(s): Lovaza arm | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin arm
C: Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MBX-8025 50 mg/Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: MBX-8025 | Arm Label: MBX-8025 100 mg/Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: MBX-8025 | Arm Label: Placebo/Atorvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Atorvastatin | Arm Label: MBX-8025 50 mg/Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin, Drug: MBX-8025 | Arm Label: MBX-8025 100 mg/Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin, Drug: MBX-8025 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MBX-8025 100 mg/Placebo, MBX-8025 50 mg/Placebo, Placebo/Atorvastatin 20 mg, Placebo/Placebo | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 50 mg/Placebo | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 100 mg/Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): MBX-8025 100 mg/Atorvastatin 20 mg, MBX-8025 50 mg/Atorvastatin 20 mg, Placebo/Atorvastatin 20 mg | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 50 mg/Atorvastatin 20 mg | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 100 mg/Atorvastatin 20 mg
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550, Drug: Atorvastatin Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Atorvastatin Placebo; Assigned to Arm(s): Arm 2

Answer: D